Art. -Nr.: HY-19536

LLL12

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.45%
CAS. Nr.: 1260247-42-4
Formel: C₁₄H₉NO₅S
Molecular Weight:303.29

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

LLL12 Chemical Structure

CAS. Nr.: 1260247-42-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

p-STAT3

Alle STAT Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	0.19 μM Compound: LLL12	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24176397]
HEL	IC₅₀	1.46 μM Compound: LLL12	Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
HPAC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
HT-29	IC₅₀	0.11 μM Compound: LLL12	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24176397]
MDA-MB-231	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
MDA-MB-468	IC₅₀	0.73 μM Compound: LLL12	Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
PANC-1	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
SJRH30	IC₅₀	0.47 μM Compound: 13, LLL12	Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay	[PMID: 23651330]
SK-BR-3	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
U2OS	IC₅₀	1 μM Compound: 13, LLL12	Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay	[PMID: 23651330]
U-373MG ATCC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
U-373MG ATCC	IC₅₀	0.86 μM Compound: 90	Antiproliferative activity against human U373 cells Antiproliferative activity against human U373 cells	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
U-87MG ATCC	IC₅₀	0.21 μM Compound: 90	Antiproliferative activity against human U87 cells Antiproliferative activity against human U87 cells	[PMID: 30583248]

In Vitro

LLL12 (0.01-1 μM; 72 h) inhibits cell viability of ovarian cancer cell lines with or without Cisplatin (0.5 μM, 2.5 μM) and Paclitaxel (0.25 μM, 0.5 μM).^[1].
LLL12 (0.25-1.0 μM; 72 h) inhibit STAT3 phosphorylation (Tyr705) in ovarian cancer cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines
Concentration:

0.25, 0.5, and 1 μM for A2780 and OVCAR5; 1, 2.5, and 5 μM for SKOV3 and CAOV-3
Incubation Time:

72 hours
Result:

Inhibited STAT3 phosphorylation at Tyr705.

In Vivo

LLL12 (5 mg/kg; i.p.; once daily for 13 d) shows strong growth inhibition activity in mouse osteosarcoma cells and tumor growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse xenografts with SJSA or OS-33 osteosarcoma cells^[2]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection; once daily for 13 days
Result:

Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice.

Chemical Information

CAS. Nr. 1260247-42-4
Appearance Solid
Molecular Weight 303.29
Formel C₁₄H₉NO₅S
Color Light yellow to yellow
SMILES

O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Phytomedicine

Puerarin mitigates cognitive decline and white matter injury via CD36-Mediated microglial phagocytosis in chronic cerebral hypoperfusion. [Abstract]

2025 Jan 16:138:156396. PMID: 39827816

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (329.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2972 mL

16.4859 mL

32.9717 mL

5 mM

0.6594 mL

3.2972 mL

6.5943 mL

10 mM

0.3297 mL

1.6486 mL

3.2972 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: 0.5 mg/mL (1.65 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. [Content Brief]

[2]. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2972 mL	16.4859 mL	32.9717 mL	82.4294 mL
	5 mM	0.6594 mL	3.2972 mL	6.5943 mL	16.4859 mL
	10 mM	0.3297 mL	1.6486 mL	3.2972 mL	8.2429 mL
	15 mM	0.2198 mL	1.0991 mL	2.1981 mL	5.4953 mL
	20 mM	0.1649 mL	0.8243 mL	1.6486 mL	4.1215 mL
	25 mM	0.1319 mL	0.6594 mL	1.3189 mL	3.2972 mL
	30 mM	0.1099 mL	0.5495 mL	1.0991 mL	2.7476 mL
	40 mM	0.0824 mL	0.4121 mL	0.8243 mL	2.0607 mL
	50 mM	0.0659 mL	0.3297 mL	0.6594 mL	1.6486 mL
	60 mM	0.0550 mL	0.2748 mL	0.5495 mL	1.3738 mL
	80 mM	0.0412 mL	0.2061 mL	0.4121 mL	1.0304 mL
	100 mM	0.0330 mL	0.1649 mL	0.3297 mL	0.8243 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LLL12

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LLL12

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LLL12

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LLL12

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LLL12 Related Classifications

Art. -Nr.: HY-19536